v3.25.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Total revenues $ 4,089 $ 308
Operating expenses:    
Research and development 53,062 55,455
Acquisition of in-process research and development 530,000 0
General and administrative 65,088 47,544
Total operating expenses 648,150 102,999
Loss from operations (644,061) (102,691)
Other income (expense), net:    
Interest income 1,478 778
Interest expense (1,162) (3,124)
Change in fair value of assets and liabilities, net (24,416) (48,879)
Gain on other investments 3,794 1,260
Gain on consolidation of Beckley Psytech 6,902 0
Change in fair value of digital assets, net (1,233) 0
Foreign exchange loss, net 1,908 (1,263)
Other income (expense), net (3,059) 5,514
Other income (expense), net (15,788) (45,714)
Net loss before income taxes (659,849) (148,405)
Benefit from (provision for) income taxes (298) 356
Losses from investments in equity method investees, net of tax 0 (2,000)
Net loss (660,147) (150,049)
Net loss attributable to noncontrolling interests (100) (780)
Net loss attributable to ATAI Life Sciences N.V. stockholders $ (660,047) $ (149,269)
Net loss per share attributable to AtaiBeckley Inc. shareholders - basic $ (2.91) $ (0.93)
Net loss per share attributable to AtaiBeckley Inc. shareholders - diluted $ (2.91) $ (0.93)
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - basic 226,532,786 160,159,983
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - diluted 226,532,786 160,159,983
License Revenue    
Total revenues $ 202 $ 308
Research and Development Services Revenue    
Total revenues $ 3,887 $ 0